

Suzanne E Dahlberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/66921/publications.pdf>

Version: 2024-02-01

116
papers

11,254
citations

26630

56
h-index

29157

104
g-index

120
all docs

120
docs citations

120
times ranked

15329
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of an Educational Video to Improve Transgender Health Care Knowledge. <i>Clinical Pediatrics</i> , 2022, 61, 412-417.	0.8	5
2	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	2.8	4
3	Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. <i>Journal of Clinical Oncology</i> , 2022, 40, 2285-2287.	1.6	1
4	Attitudes towards involving children in decision-making surrounding lung transplantation. <i>Pediatric Pulmonology</i> , 2021, 56, 1534-1542.	2.0	1
5	Peer-to-Peer Social Media Communication About Dietary Supplements Used for Weight Loss and Sports Performance Among Military Personnel: Pilot Content Analysis of 11 Years of Posts on Reddit. <i>JMIR Formative Research</i> , 2021, 5, e28957.	1.4	4
6	Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). <i>JTO Clinical and Research Reports</i> , 2021, 2, 100166.	1.1	1
7	Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 960-967.	1.1	4
8	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. <i>Nature Medicine</i> , 2021, 27, 1910-1920.	30.7	62
9	Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. <i>Journal of Thoracic Imaging</i> , 2020, 35, 101-107.	1.5	7
10	Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4072-4079.	7.0	13
11	Clinical Versus Statistical Significance in Studies of Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1406-1408.	1.1	10
12	Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. <i>European Journal of Radiology Open</i> , 2020, 7, 100210.	1.6	4
13	Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2393-2403.	7.0	27
14	Reply to N. Hanna et al and L. Xie et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 771-772.	1.6	0
15	Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. <i>Journal of Clinical Oncology</i> , 2019, 37, 2360-2367.	1.6	52
16	M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. <i>Oncologist</i> , 2019, 24, e749-e754.	3.7	5
17	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102.	2.0	85
18	Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. <i>Journal of Clinical Oncology</i> , 2019, 37, 1927-1934.	1.6	220

#	ARTICLE	IF	CITATIONS
19	Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. <i>European Journal of Radiology Open</i> , 2019, 6, 128-131.	1.6	23
20	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. <i>Cancer Discovery</i> , 2019, 9, 926-943.	9.4	220
21	Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 222-229.	1.6	133
22	Cytologicâ€histologic correlation of programmed deathâ€ligand 1 immunohistochemistry in lung carcinomas. <i>Cancer Cytopathology</i> , 2018, 126, 253-263.	2.4	70
23	Evaluation of End Points in Cancer Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2018, 13, 745-747.	1.1	2
24	Safety of Programmed Deathâ€1 Pathway Inhibitors Among Patients With Nonâ€Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. <i>Journal of Clinical Oncology</i> , 2018, 36, 1905-1912.	1.6	268
25	Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. <i>European Journal of Radiology</i> , 2018, 109, 68-76.	2.6	8
26	Interpretation of Results from Underâ€accruing Studies. <i>Oncologist</i> , 2018, 23, 755-756.	3.7	0
27	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	1.1	85
28	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1625-1637.	1.1	10
29	Assessment of Resistance Mechanisms and Clinical Implications in Patients With <i>EGFR</i> -T790Mâ€Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , 2018, 4, 1527.	7.1	522
30	Pragmatic approaches to address expansion cohort design. <i>Cancer</i> , 2018, 124, 3290-3292.	4.1	2
31	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1610-1623.	10.7	136
32	Tumor Response Dynamics of Advanced Nonâ€small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017, 23, 5737-5744.	7.0	69
33	Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensiveâ€stage small cell lung cancer: A trial of the ECOGâ€ACRIN Cancer Research Group (E1508). <i>Cancer</i> , 2016, 122, 2371-2378.	4.1	57
34	Prospective Validation of Rapid Plasma Genotyping for the Detection of <i>EGFR</i> and <i>KRAS</i> Mutations in Advanced Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 1014.	7.1	516
35	Activity of erlotinib when dosed below the maximum tolerated dose for <i>EGFR</i> -mutant lung cancer: Implications for targeted therapy development. <i>Cancer</i> , 2016, 122, 3456-3463.	4.1	15
36	Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 1818-1828.	1.2	88

#	ARTICLE	IF	CITATIONS
37	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1661-1671.	10.7	115
38	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. <i>Clinical Cancer Research</i> , 2016, 22, 6010-6020.	7.0	100
39	Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3148-3156.	7.0	71
40	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. <i>Journal of Thoracic Oncology</i> , 2016, 11, 556-565.	1.1	268
41	Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. <i>Academic Radiology</i> , 2016, 23, 329-336.	2.5	33
42	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. <i>Journal of Clinical Oncology</i> , 2016, 34, 721-730.	1.6	549
43	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 313.	7.1	171
44	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1726-1735.	1.1	208
45	Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1099-1106.	1.1	39
46	Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). <i>Cancer</i> , 2015, 121, 2253-2261.	4.1	21
47	Improving Clinical Trial Efficiency: Thinking outside the Box. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e141-e147.	3.8	57
48	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	7.0	104
49	Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. <i>Lung Cancer</i> , 2015, 88, 108-111.	2.0	369
50	A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). <i>Lung Cancer</i> , 2015, 89, 66-70.	2.0	52
51	Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. <i>European Journal of Radiology</i> , 2015, 84, 998-1004.	2.6	54
52	Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. <i>Cancer</i> , 2015, 121, 2570-2577.	4.1	42
53	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2851-2860.	7.0	96
54	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63.	1.1	119

#	ARTICLE	IF	CITATIONS
55	Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. <i>Leukemia</i> , 2015, 29, 526-534.	7.2	265
56	Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	45
57	E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 171-180.	2.3	3
58	Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 177-183.	2.3	21
59	Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2014, 59, 409-418.e3.	1.1	128
60	Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2013, 119, 3761-3768.	4.1	40
61	A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 2972-2978.	2.8	166
62	Fate of the contralateral limb after lower extremity amputation. <i>Journal of Vascular Surgery</i> , 2013, 58, 1571-1577.e1.	1.1	38
63	Oncogenic mutations in cervical cancer. <i>Cancer</i> , 2013, 119, 3776-3783.	4.1	225
64	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. <i>Lancet Oncology</i> , The, 2013, 14, 619-626.	10.7	203
65	Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. <i>Lung Cancer</i> , 2013, 81, 47-52.	2.0	15
66	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2013, 79, 283-288.	2.0	68
67	Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. <i>Journal of Clinical Oncology</i> , 2013, 31, 1202-1210.	1.6	274
68	Outcomes following infrapopliteal angioplasty for critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2013, 57, 1455-1464.	1.1	77
69	Baseline tumour measurements predict survival in advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2013, 109, 1476-1481.	6.4	30
70	Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions. <i>Journal of Thoracic Oncology</i> , 2013, 8, 179-184.	1.1	269
71	Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Patients Treated with EGFR TKI. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1059-1068.	1.1	48
72	Body Mass Index and Its Association with Clinical Outcomes for Advanced Non-Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1121-1127.	1.1	87

#	ARTICLE	IF	CITATIONS
73	Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1295-1307.	1.1	16
74	Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. <i>Pediatrics</i> , 2012, 130, 1003-1011.	2.1	142
75	Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation. <i>Cancer Discovery</i> , 2012, 2, 47-55.	9.4	89
76	Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 881-94.	2.4	72
77	Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non-Small-Cell Lung Cancer: The ECOG 3598 Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 616-622.	1.6	75
78	SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. <i>Oncogene</i> , 2012, 31, 4107-4116.	5.9	44
79	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. <i>Nature Medicine</i> , 2012, 18, 1118-1122.	30.7	162
80	Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 1042-1049.	1.6	273
81	Prognostic Models to Predict Survival in Non-Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1361-1368.	1.1	57
82	Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 2788-2797.	1.6	227
83	Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. <i>Lung Cancer</i> , 2012, 76, 410-415.	2.0	30
84	The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. <i>Oncology Reports</i> , 2011, 25, 1765-72.	2.6	21
85	The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 4169-4173.	1.4	162
86	Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599. <i>Journal of Thoracic Oncology</i> , 2011, 6, 103-108.	1.1	57
87	The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. <i>British Journal of Haematology</i> , 2011, 152, 452-459.	2.5	216
88	Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: Report from Dana-Farber Cancer Institute ALL Consortium Protocol 0001. <i>Pediatric Blood and Cancer</i> , 2011, 57, 492-498.	1.5	38
89	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2011, 208, 1595-1603.	8.5	104
90	Abstract 87: SULF2 methylation is a prognostic biomarker for lung cancer survival and increases sensitivity to camptothecin analogues via expression of ISG15. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
91	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. <i>Journal of Cell Biology</i> , 2011, 194, i4-i4.	5.2	1
92	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. <i>Blood</i> , 2011, 118, 1405-1405.	1.4	2
93	Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 2845-2851.	1.4	112
94	Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: An Eastern Cooperative Oncology Group Study. <i>Journal of Thoracic Oncology</i> , 2010, 5, 885-892.	1.1	31
95	Clinical Course of Advanced Nonâ€“Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599. <i>Journal of Clinical Oncology</i> , 2010, 28, 949-954.	1.6	220
96	Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1416-1423.	1.1	153
97	Absence of Biallelic γ TCR Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3816-3823.	1.6	93
98	A Pilot Trial of Rapamycin with Glucocorticoids In Children and Adults with Relapsed ALL. <i>Blood</i> , 2010, 116, 3244-3244.	1.4	0
99	Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501. <i>Journal of Clinical Oncology</i> , 2009, 27, 6006-6011.	1.6	148
100	Population-Based Outcomes Following Endovascular and Open Repair of Ruptured Abdominal Aortic Aneurysms. <i>Journal of Endovascular Therapy</i> , 2009, 16, 554-564.	1.5	92
101	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 647-650.	1.4	414
102	Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginaseâ€“associated pancreatitis. <i>Pediatric Blood and Cancer</i> , 2009, 53, 162-167.	1.5	137
103	Predictors of failure after angioplasty of infrainguinal vein bypass grafts. <i>Journal of Vascular Surgery</i> , 2009, 49, 117-121.	1.1	28
104	The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols.. <i>Blood</i> , 2009, 114, 3073-3073.	1.4	1
105	Gefitinib for Recurrent Nonâ€“Small-Cell Lung Cancer: All Things Are Not Created Equal. <i>Journal of Clinical Oncology</i> , 2008, 26, 4233-4235.	1.6	4
106	Meaningful Subset Analyses Contribute to Optimal Patient Care. <i>Journal of Clinical Oncology</i> , 2008, 26, 2064-2065.	1.6	0
107	Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane. <i>Journal of Clinical Oncology</i> , 2008, 26, 1106-1111.	1.6	111
108	Outcomes for Elderly, Advanced-Stage Nonâ€“Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. <i>Journal of Clinical Oncology</i> , 2008, 26, 60-65.	1.6	358

#	ARTICLE	IF	CITATIONS
109	P1-052: Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker. <i>Journal of Thoracic Oncology</i> , 2007, 2, S570.	1.1	5
110	A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500). <i>Journal of Thoracic Oncology</i> , 2007, 2, 1036-1041.	1.1	145
111	Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. <i>Blood</i> , 2007, 110, 1607-1611.	1.4	126
112	Lower extremity arterial revascularization in obese patients. <i>Journal of Vascular Surgery</i> , 2007, 46, 738-742.	1.1	35
113	PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. <i>Journal of Thoracic Oncology</i> , 2007, 2, S468.	1.1	1
114	A Proportional Hazards Cure Model for the Analysis of Time to Event with Frequently Unidentifiable Causes. <i>Biometrics</i> , 2007, 63, 1237-1244.	1.4	2
115	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007, 110, 587-587.	1.4	47
116	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2006, 108, 1858-1858.	1.4	4